Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic ...

Lineage Cell Therapeutics (LCTX) announced that the Company has initiated the DOSED clinical study. The DOSED study will evaluate the safety ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/2.3cY8rBmp.js ...

Lineage Cell (LCTX) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting ...

CARLSBAD, Calif.--(BUSINESS WIRE)--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical ...

HC Wainwright reissued their buy rating on shares of Lineage Cell Therapeutics (NYSEAMERICAN:LCTX – Free Report) in a report released on Tuesday morning,Benzinga reports. The firm currently has a ...

Mesenchymal lineage precursors can be reproducibly isolated from adult mammalian bone marrow and grown in culture. Immunoselection with monoclonal antibodies against STRO-1 and vascular-cell ...

Lineage Cell Therapeutics initiates DOSED clinical study of OPC1 for spinal cord injury: Carlsbad, California Thursday, February 13, 2025, 14:00 Hrs [IST] Lineage Cell Therapeutic ...

Joseph Pantginis, an analyst from H.C. Wainwright, reiterated the Buy rating on Lineage Therap (LCTX – Research Report). The associated price ...